Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.42 |
| ▸ | CCR1 | P32246 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5546014 | 0.89 | CHRM3 (0.49) | CHRM3CHRM2CHRM1CCR1 | |
| Trifluoroacetic Acid SCHEMBL5533187 | 0.89 | CHRM3 (0.49) | CHRM3CHRM2CHRM1CCR1 | |
| SCHEMBL5538287 | 0.88 | CHRM3 (0.50) | CHRM3CHRM2CHRM1CCR1PPARG | |
| Trifluoroacetic Acid SCHEMBL5535488 | 0.87 | CHRM3 (0.46) | CHRM3CHRM2CHRM1CCR1 | |
| Bromide SCHEMBL5546045 | 0.85 | CHRM3 (0.65) | CHRM3CHRM2CHRM1CCR1 | |
| Trifluoroacetic Acid SCHEMBL5544783 | 0.85 | CHRM3 (0.49) | CHRM3CHRM2CHRM1CCR1 | |
| Trifluoroacetic Acid SCHEMBL6414381 | 0.84 | CHRM3 (0.44) | CHRM3CHRM2CHRM1CCR1 | |
| Trifluoroacetic Acid SCHEMBL5538291 | 0.84 | CHRM3 (0.44) | CHRM3CHRM2CHRM1CCR1 | |
| Trifluoroacetic Acid SCHEMBL6420994 | 0.82 | CHRM3 (0.45) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6423109 | 0.81 | CHRM3 (0.54) | CHRM3CHRM2CHRM1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129420-A1 | New pyrrolidinium derivatives | ALMIRALL PRODESFARMA SA | 2007-06-07 | — | — | US | claimed |
| US-20050282875-A1 | Pyrrolidinium derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2005-12-22 | — | — | US | claimed |
| EP-1497284-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | Almirall Prodesfarma AG (CH) | 2005-01-19 | — | — | EP | claimed |
| WO-2003087094-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | ALMIRALL PRODESFARMA AG (CH) | 2003-10-23 | — | — | WO | claimed |
| US-20070129420-A1 | New pyrrolidinium derivatives | ALMIRALL PRODESFARMA SA | 2007-06-07 | — | — | US | disclosed |
| US-7192978-B2 | Pyrrolidinium derivatives | ALMIRALL PRODESFARMA AG (CH) | 2007-03-20 | — | — | US | disclosed |
| US-20050282875-A1 | Pyrrolidinium derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2005-12-22 | — | — | US | disclosed |
| EP-1497284-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | Almirall Prodesfarma AG (CH) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087094-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | ALMIRALL PRODESFARMA AG (CH) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282875-A1 | Pyrrolidinium derivatives | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20070129420-A1 | New pyrrolidinium derivatives | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.